Insulin Drug By Eli Lilly And Co (NYSE:LLY) Performs Better Than Lantus From Sanofi SA (ADR) (NYSE:SNY) In Trials

Eli Lilly and Co (NYSE:LLY) has a reason to celebrate as their insulin drug registered better results than the current top-selling drug called Lantus that was developed by Sanofi SA (ADR) (NYSE:SNY). Lilly’s insulin recorded better results in terms of blood sugar reduction for type two diabetes compared to Lantus. The data was collected from […]

Sanofi SA (ADR) (NYSE:SNY) Adds Gene Therapy Project And $300 Million To Selecta Deal

Sanofi SA (ADR) (NYSE:SNY) has added $300 million to its collaboration with Selecta Biosciences to develop a vaccination for the treatment of celiac disease and achieve other research innovations. The company is also mulling to join hands with Genethon to making the treatments safe across diverse categories if the need arises. Selecta has also entered […]

Gilead Sciences, Inc. (NASDAQ:GILD) Gaffe Leads Drug Makers To Pledge More Openness On Price

Drug makers are worried about the market reaction over increasing drug prices especially after what happened to Gilead Sciences, Inc. (NASDAQ:GILD) over the Solvadi cure for Hepatitis C. Drug companies such as Sanofi SA (ADR) (NYSE:SNY) and Biogen Inc (NASDAQ:BIIB) expressed their concerns following the undesirable response that Gilead received in 2013. The company had […]

Sanofi SA (ADR )(NYSE:SNY) backed MyoKardia Raises $46 million In Latest Round

Sanofi SA (ADR )(NYSE:SNY) backed MyoKardia is getting more injection of capital. Sanofi had gotten a $10 million piece of equity when it collaborated with Myokardia. MyoKardia has gotten $46 million in its Series B as it plans the next stage of its development of new drugs for heart patients with genetically defined groups. Cowen […]

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) CEO Steps Down After Less Than A Year, Leaving A Biotech On The Mend

Anne Whitaker is stepped down as CEO of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) just nine months after she got the position. Whitaker left the company in a state of disarray as the company tries to cut down its operations to limit losses. The former CEO joined Synta less than a year ago after leaving Sanofi SA […]

The Market Outlook: Durata Therapeutics (DRTX), Unilife Corp (UNIS), Revolution Lighting Technologies (RVLT)

Boston, MA 10/06/2014 (wallstreetpr) – Durata Therapeutics Inc (NASDAQ:DRTX) has agreed to be purchased by Actavis plc (NYSE:ACT). The deal is expected to complete later this year or early next year. DRTX has been offered $23 per share, which suggests 66% premium from the previous closing price before the deal was made public. The companies said […]

VIVUS, Inc. (NASDAQ:VVUS) – Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use

Boston, MA 09/19/2014 (wallstreetpr) – Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the nod by the U.S. Food and Drug Administration to be used 15 minutes earlier. It is crucial to point out here that this drug was already approved by the FDA, […]

CEO Alan Shortall Talks On Unilife Corp (NASDAQ:UNIS) 4Q2014 Results

Boston, MA 09/11/2014 (wallstreetpr) – Alan Shortall, Chairman and the CEO of Unilife Corp (NASDAQ:UNIS) discussed the fourth quarter results on a conference call held on Wednesday. Shortall started the talks on the positive note as he said that the management is delighted with the trajectory of the business. Unilife is well positioned to deliver […]

Sanofi SA (ADR) (NYSE:SNY) Gets Clearance From The Competition Commission of India In Relation With Apollo Deal

Boston, MA 08/28/2014 (wallstreetpr) – According to reports, Sanofi SA (ADR) (NYSE:SNY) has got the green light from the Competition Commission of India in regard with its proposed purchase deal of an arm of Apollo. The representatives of CCI said that they did not found any sign of unfair business practice in this deal. What’s […]

Eli Lilly and Co (NYSE:LLY) Gets FDA Tentative Approval for Diabetes Drug

Boston, MA 08/19/2014 (wallstreetpr) – Eli Lilly and Co (NYSE:LLY) received positive news on its insulin injection that can be used to control sugar levels in diabetic patients after the FDA granted it tentative approval. The drug named, Basaglar, can be used to provide long lasting blood sugar control when patients are taking their meals […]

Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal

Boston, MA 08/11/2014 (wallstreetpr) – French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and marketing of the inhaled insulin therapy, Afrezza, targeting adults with types 1 and 2 of diabetes. Afrezza is billed as rapid-acting inhaled insulin, a new solution for diabetes patients that […]

Sanofi SA (ADR) (NYSE:SNY) Walks Out From KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)’s KB001-A Deal

Boston, MA 07/29/2014 (wallstreetpr) – During the 2013’s era of biotech boom, KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) had debuted on the exchange with high promises to deliver, which had instantly caught attention of giants like Sanofi SA (ADR) (NYSE:SNY). The latter had agreed to partner KaloBios in a deal by paying $35 million and had announced […]

Receptos Inc (NASDAQ:RCPT) Raising Funds For Product Development

Boston, MA 06/19/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) has turned to equity offering to raise funds for the development of its lead drug candidate PRC1063 and others. The drug is going through Phase III trial after showing compelling results in its Phase II study. The treatment targets multiple sclerosis (MS). The company has announced offering of […]

Sanofi SA (ADR) (NYSE:SNY) And Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Reported Success In Phase II Study With Rheumatoid Arthritis Drug

Boston, MA 06/12/2014 (wallstreetpr) – Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced successful results from a Phase III study of experimental drug sarilumab in treating rheumatoid arthritis (RA) in patients who had previously shown no response to  methotrexate (MTX) treatment. The pharmaceutical companies presented their new data which demonstrated that sarilumab is capable […]

Sanofi SA (ADR) (NYSE:SNY)’s Shan5 Regains WHO Prequalification Status

Boston, MA 05/06/2014 (wallstreetpr) – After four years of disqualification, Sanofi SA (ADR) (NYSE:SNY)‘s five-in-one vaccine, dubbed Shan5, for children is granted prequalification status by the World Health Organization (WHO). Re-Opens Door For UN Agencies The prequalification status will open up the sale of the vaccine to the United Nations agencies like UNICEF and will […]